scPharmaceuticals Inc. (NASDAQ:SCPH) Short Interest Down 15.0% in March

scPharmaceuticals Inc. (NASDAQ:SCPH) saw a significant decline in short interest during the month of March. As of March 31st, there was short interest totalling 4,820,000 shares, a decline of 15.0% from the March 15th total of 5,670,000 shares. Based on an average trading volume of 441,300 shares, the short-interest ratio is presently 10.9 days. Approximately 10.2% of the shares of the stock are short sold.

scPharmaceuticals Stock Performance

Shares of NASDAQ SCPH opened at $2.57 on Tuesday. The company has a 50-day simple moving average of $2.90 and a 200-day simple moving average of $3.39. The company has a debt-to-equity ratio of 1.66, a current ratio of 8.08 and a quick ratio of 6.89. The company has a market cap of $129.23 million, a PE ratio of -1.35 and a beta of 0.38. scPharmaceuticals has a 12 month low of $1.94 and a 12 month high of $5.65.

scPharmaceuticals (NASDAQ:SCPH) last released its earnings results on Wednesday, March 19th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.05. scPharmaceuticals had a negative net margin of 264.60% and a negative return on equity of 244.93%. The firm had revenue of $12.15 million during the quarter, compared to analysts’ expectations of $12.08 million. On average, equities analysts anticipate that scPharmaceuticals will post -1.53 earnings per share for the current year.

Hedge Funds Weigh In On scPharmaceuticals

Several large investors have recently added to or reduced their stakes in the business. State Street Corp increased its stake in shares of scPharmaceuticals by 5.2% during the 3rd quarter. State Street Corp now owns 682,135 shares of the company’s stock valued at $3,111,000 after acquiring an additional 33,879 shares during the last quarter. XTX Topco Ltd purchased a new position in scPharmaceuticals during the third quarter worth approximately $124,000. Barclays PLC boosted its holdings in shares of scPharmaceuticals by 317.2% in the 3rd quarter. Barclays PLC now owns 40,644 shares of the company’s stock valued at $186,000 after purchasing an additional 30,902 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of scPharmaceuticals by 10.6% during the 3rd quarter. Geode Capital Management LLC now owns 643,342 shares of the company’s stock valued at $2,934,000 after buying an additional 61,582 shares during the period. Finally, Virtu Financial LLC acquired a new stake in shares of scPharmaceuticals during the 3rd quarter worth $46,000. 89.52% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have recently commented on SCPH shares. HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of scPharmaceuticals in a research report on Thursday, March 20th. Maxim Group lowered their target price on scPharmaceuticals from $20.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, March 20th.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.